Author

Shanisha Gordon-Mitchell

Albert Einstein College of MedicineORCID 0009-0007-5335-0046Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

Kith PradhaniD· 2 shared Abdullah KhasawnehiD· 1 shared Aditi ShastriiD· 1 shared Aishwarya KulkarniiD· 1 shared Amit K. VermaiD· 1 shared Amit VermaiD· 1 shared Anna SkwarskaiD· 1 shared Ariel A. Fromowitz· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Kith PradhanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyLeukemiaPeer-reviewedFeb 17, 2026

A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid Leukemia

Samarpana Chakraborty, Claudia Morganti, Kimberly S. Zaldana…·Aditi Shastri

This paper shows that targeting STAT3 with a degrader can overcome Venetoclax resistance in AML by reducing MCL1 and improving mitochondrial function.

14 citationstop 1%

mouseproteomics

𝕏 PostBluesky

Cancer BiologyScience Translational MedicinePeer-reviewedMay 7, 2025

Broad de-regulated U2AF1 splicing is prognostic and augments leukemic transformation via protein arginine methyltransferase activation

Meenakshi Venkatasubramanian, Leya Y Schwartz, Nandini Ramachandra…·Nathan Salomonis

The paper identifies a splicing mechanism in AML independent of mutations, showing it drives poor prognosis and can be targeted with PRMT5 inhibition.

12 citations

humanbulk RNA-seq

𝕏 PostBluesky